Antibiotics: Azithromycin associated with risk of potentially fatal irregular heart rhythm


The Food and Drug Administration ( FDA ) warned the public that Azithromycin ( Zithromax or Zmax ) can cause abnormal changes in the electrical activity of the heart that may lead to a potentially fatal irregular heart rhythm. Patients at particular risk for developing this condition include those with known risk factors such as existing QT interval prolongation, low blood levels of potassium or magnesium, a slower than normal heart rate, or use of certain drugs used to treat abnormal heart rhythms, or arrhythmias.

FDA has issued a Drug Safety Communication as a result of a review of a study by medical researchers as well as another study by a manufacturer of the drug that assessed the potential for Azithromycin to cause abnormal changes in the electrical activity of the heart.

FDA previously released a Statement on May 17, 2012, about a study that compared the risks of cardiovascular death in patients treated with the antibacterial drugs Azithromycin, Amoxicillin, Ciprofloxacin ( Cipro ), and Levofloxacin ( Levaquin ), or no antibacterial drug.
The study reported an increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a 5-day course of Azithromycin ( Zithromax ) compared to persons treated with Amoxicillin, Ciprofloxacin, or no drug. The risks of cardiovascular death associated with Levofloxacin treatment were similar to those associated with Azithromycin treatment.

FDA-approved indications for Azithromycin include: acute bacterial exacerbations of chronic obstructive pulmonary disease, acute bacterial sinusitis, community-acquired pneumonia, pharyngitis / tonsillitis, uncomplicated skin and skin structure infections, urethritis and cervicitis, genital ulcer disease.

Recommendation

Health care professionals should consider the risk of torsades de pointes and fatal heart rhythms with Azithromycin when considering treatment options for patients who are already at risk for cardiovascular events. FDA notes that the potential risk of QT prolongation with Azithromycin should be placed in appropriate context when choosing an antibacterial drug. Alternative drugs in the macrolide class, or non-macrolides such as the fluoroquinolones, also have the potential for QT prolongation or other significant side effects that should be considered when choosing an antibacterial drug. ( Xagena )

Source: FDA, 2013

XagenaMedicine_2013



Indietro

Altri articoli

Fungal infections that are resistant to treatment are an emerging public health problem, but everyone has a role in preventing...


The U.S. Food and Drug Administration ( FDA ) has advised that the serious side effects associated with fluoroquinolone antibacterial...


Office of Orphan Products Development ( OOPD ) of the Food and Drug Administration ( FDA ) has granted orphan...


The FDA ( Food and Drug Administration ) has concluded that Doribax ( Doripenem ), an antibacterial drug that has...


The FDA ( Food and Drug Administration ) has approved Xtoro ( Finafloxacin otic suspension ), a new drug used...


The FDA ( Food and Drug Administration ) has approved Sivextro ( Tedizolid phosphate ), a new antibacterial drug, to...


Use of Nitrofurantoin for urinary tract infections is contraindicated in patients with less than 60 mL/min creatinine clearance. Healthcare professionals...


Chronic bacterial prostatitis ( CBP ) is frequently diagnosed in men of fertile age, and is characterized by a disabling...


The FDA ( Food and Drug Administration ) has approved Altabax ( Retapamulin ointment ) for topical treatment of impetigo...